Voskaridou E - Search Results

1

2017 Clinical trials update in new treatments of β-thalassemia.

Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E. Makis A, et al. Among authors: voskaridou e. Am J Hematol. 2016 Nov;91(11):1135-1145. doi: 10.1002/ajh.24530. Am J Hematol. 2016. PMID: 27502996 Free article. Review.

2

Hb Arta [beta 45 (CD4) Phe-->Cys]: a new unstable haemoglobin with reduced oxygen affinity in trans with beta-thalassaemia.

Vassilopoulos G, Papassotiriou I, Voskaridou E, Stamoulakatou A, Premetis E, Kister J, Marden M, Griffon N, Poyart C, Wajcman H. Vassilopoulos G, et al. Among authors: voskaridou e. Br J Haematol. 1995 Nov;91(3):595-601. doi: 10.1111/j.1365-2141.1995.tb05353.x. Br J Haematol. 1995. PMID: 8555060

3

Neutrophil elastase in patients with homozygous beta-thalassemia and pseudoxanthoma elasticum-like syndrome.

Samarkos M, Aessopos A, Fragodimitri C, Karagiorga M, Kalotychou V, Voskaridou E, Kavouklis E, Loukopoulos D. Samarkos M, et al. Among authors: voskaridou e. Am J Hematol. 2000 Feb;63(2):63-7. doi: 10.1002/(sici)1096-8652(200002)63:2<63::aid-ajh1>3.0.co;2-4. Am J Hematol. 2000. PMID: 10629570 Free article. Clinical Trial.

4

Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.

Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D. Papassotiriou I, et al. Among authors: voskaridou e. Hematol J. 2000;1(5):295-300. doi: 10.1038/sj.thj.6200049. Hematol J. 2000. PMID: 11920206

5

Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D. Voskaridou E, et al. Br J Haematol. 2004 Sep;126(5):736-42. doi: 10.1111/j.1365-2141.2004.05104.x. Br J Haematol. 2004. PMID: 15327528 Free article.

6

Deferiprone as an oral iron chelator in sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Stamoulakatou A, Meletis J, Ourailidis A, Papassotiriou I, Loukopoulos D. Voskaridou E, et al. Ann Hematol. 2005 Jul;84(7):434-40. doi: 10.1007/s00277-005-1015-7. Epub 2005 Apr 5. Ann Hematol. 2005. PMID: 15809885 Clinical Trial.

7

Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, Simirloglou D, Loukopoulos D, Papassotiriou I. Voskaridou E, et al. Kidney Int. 2006 Jun;69(11):2037-42. doi: 10.1038/sj.ki.5000248. Kidney Int. 2006. PMID: 16501491 Free article.

8

Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis.

Voskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I, Terpos E. Voskaridou E, et al. Haematologica. 2006 Jun;91(6):813-6. Epub 2006 May 16. Haematologica. 2006. PMID: 16704959

9

Pathogenesis and management of osteoporosis in thalassemia.

Voskaridou E, Terpos E. Voskaridou E, et al. Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:86-93. Pediatr Endocrinol Rev. 2008. PMID: 19337161 Review.

10

Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.

Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M, Terpos E. Voskaridou E, et al. Ann Hematol. 2011 Jan;90(1):11-5. doi: 10.1007/s00277-010-1029-7. Epub 2010 Jul 27. Ann Hematol. 2011. PMID: 20661572 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page